Maxim Group analyst Jason McCarthy reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) on Tuesday, setting a price target of $20, which is approximately 99.60% above the present share price of $10.02.
McCarthy expects Inovio Pharmaceuticals to post earnings per share (EPS) of $0.12 for the first quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Inovio Pharmaceuticals, with an average price target of $17.17.
The analysts price targets range from a high of $35 to a low of $7.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $236.18 thousand and a net profit of -$36.33 million. The company's market cap is $2.05 billion.
According to TipRanks.com, Maxim Group analyst Jason McCarthy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 58.4% and a 60.15% success rate.
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.